Together since 2007

Transforming money management to make financial markets accessible to all

Acquired since 2021

Enabling the human right of mobility to all

Acquired since 2017

Introducing Zero Trust mechanisms for a truly sale environment

Acquired since 1994

Introduced cyber security to the mass business market

Together since 2010

Harnessing the power of artificial vision to transform the lives of visually impaired

Together since 2020

Digital Learning Platform designed to optimize student engagement and learning outcome

Together since 2019

AI-driven end-to-end Fix & Flip platform

Together since 2021

First drone delivery service focused in the US suburbs.

Acquired by DG 2007

Global provider of digital advertising solutions that optimize the use of media, creative and data for enhanced performance.

Together since 2010

Leading investment house in Israel, managing over 77 Billion Dollars for private, business and institutional clients

Together since 2016

Developing and commercializing novel endovascular treatments for stroke

Together since 2012

Developing percutaneous implantable technologies for patients with chronic heart failure


Early Experience in Class III Heart Failure Patients was Favorable.

Posted March 28, 2016

V-Wave Ltd, maker of an investigational interatrial shunt device for patients with advanced heart failure
(HF), announced today the results of its first human implants were published in The Lancet.  The study,
performed at the Quebec Heart and Lung Institute, Laval University, Quebec, Canada, was led by structural
heart disease expert, Josep Rodés-Cabau, MD. The first 10 consecutive patients had Class III symptoms
despite being treated with maximally tolerated HF medications and had poor left ventricular function. All
were successfully implanted with the shunt during a minimally invasive procedure that took generally less
than one hour, and were discharged home the next morning. There were no device-related adverse effects.
After three months, patients had significant improvements in symptoms, exercise capacity and quality-of-life assessments. Catheter measurements showed lowering of left atrial pressure without deterioration of right
heart function. These findings are consistent with the shunt diverting just the right amount of blood from
the left-side to the right-side of the heart.

“We are excited that our first scientific paper merited publication in such a leading, high-impact peer
review journal,” said Dr. William Abraham, MD, Steering Committee Chairman and Director of Cardiovascular
Medicine at The Ohio State University Wexner Medical Center. “Studies in larger populations with longer term follow-up are ongoing and a pivotal, randomized, controlled trial targeting patients in North America, the
EU and Israel, is being planned.  From these data, we hope to understand the safety, efficacy and patient
populations most likely to benefit from interatrial shunting. There is good reason to expect the V-Wave
Shunt will be helpful not only in patients with reduced left ventricular function but also in the nearly
one-half of HF patients where it is preserved.”

HF is the end-stage of most forms of heart disease, affecting six million Americans.  Despite advances in
therapy, premature death, recurrent hospitalization and deteriorating quality-of-life remain a growing
problem and represent a large burden to healthcare systems.

Principal Investigators Named
V-Wave also announced the names of four Co-Principal Investigators who will guide the company’s future
clinical trials program

Gregg Stone, MD, Professor of Medicine at Columbia University is an interventional cardiologist and
structural heart disease specialist.
Joann Lindenfeld, MD, Professor of Medicine at Vanderbilt University and current President of the Heart
Failure Society of America.
Stefan D Anker, MD, Professor for Innovative Clinical Trials, University Medicine Göttingen, Germany, is
Councillor of the Board of the European Society of Cardiology.
Josep Rodés-Cabau, MD, Associate Professor of Medicine at Laval University, Quebec, has the most experience
implanting the V-Wave Shunt.
All are experienced and widely published academicians, noted clinical trialists and recognized authorities
in their specialties.

“We are fortunate to have a most talented and respected team of Principal Investigators,” said Dr. Neal
Eigler, MD and CEO of V-Wave, “With their expert direction, we can develop the scientific basis for
interatrial shunting to support applications for regulatory approvals and hasten physician adoption, both in the U.S. and around the world.  We believe the V-Wave Shunt has the potential to change the way care is
given and fundamentally improve the lives of patients with severe heart failure.”

About V-Wave Ltd.
V-Wave Ltd., is a privately-held medical device company with offices in Israel and the U.S. Venture
investors include BRM Group, Pontifax, TriVentures, Pura Vida Investments, BioStar Ventures and strategic
investors Edwards Lifesciences and Johnson & Johnson Innovation – JJDC Inc. For further information, visit

This press release contains forward-looking statements that involve risks and uncertainties, including
statements related to clinical development and potential regulatory approval of V-Wave’s products.  All
forward-looking statements are based on information available to V-Wave as of the date hereof, and the
Company assumes no obligation to update any such forward-looking statements or information. The company’s
actual results could differ materially from those described in the company’s forward-looking statements.

CAUTION—Investigational Device.  Limited by Federal (or United States) Law to Investigational Use.